natgillin/translations-raw huggingface dataset:
Method according to any of the preceding claims, wherein the transferring comprises subjecting the liquid effluent to aeration, thereby forming a gas phase comprising air and methane. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 8-10, naznačen time da transferiranje obuhvaća podvrgavanje tekuće otpadne vode aeriranju čime se formira plinska faza koja sadrži zrak i metan.
Where m or n are 3, two or all of the substituents may be the same, or all three may be different. 
Tamo gdje m ili n su 3, dva ili svi supstituenti mogu biti jednaki, ili sva tri mogu biti različiti.
The method according to claim 24, wherein Ra2 is selected from hydrogen, C1-C6 alkyl substituted with heterocyclyl, unsubstituted C1-C6 alkoxy, amino, and heterocycle. 
Farmaceutski sastav za uporabu prema zahtjevu 2, naznačen time, da je Ra, odabran od sljedećih: vodik, C,-Cg alkil supstituiran s heterociklom, nesupstituirani C,-Cg alkoksi, amino i heterocikl.
After stirring overnight at room temperature, the reaction mixture is diluted with water (5 ml) and stirred vigorously for 10 minutes. 
Nakon miješanje preko noći pri sobnoj temperaturi, reakcijsku smjesu se razrijedi s vodom (5 ml) i miješa se snažno 10 minuta.
Specifically, the present invention provides a method of recycling solid supports for cultivation of anchorage-dependent cells such as, e.g., microcarriers and Fibra-Cel® disks. 
Točnije, ovaj izum osigurava postupak za recikliranje krutih potpora za uzgoj stanica koje potrebuju pričvršćivanje poput, na primjer, mikronosača i diskova Fibra-Cel*.
biodegrading said final product in a composting installation, and wherein said thermoplastic polymer is a Styrene-Butadiene-Styrene (SBS) block copolymer, or Styrene-Isoprene-Styrene (SIS) block copolymer, or Styrene-Butadiene, Isoprene-Styrene (SBIS) block copolymer. 
biorazgradnja spomenutog završnog proizvoda u postrojenju kompostiranja naznačena time da je spomenuti termoplastični polimer Stiren-Butadien-Stirena (SBS) blok-koplimer, ili Stiren-Isopren-Stiren (SIS) blok-koplimer, ili Stiren-Butadien, Izopren-Stiren (SBIS) blok kopolimer.
The process of claim 1, wherein said first base is selected from the group consisting of triethylamine; 1,5-diazabicyclo[4,3,0]non-5-ene 1,4-diazabicyclo[2,2,2]octane; and 1,8-diazabicyclo[5,4,0]undec-7-ene; and mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 36, wherein saidprvu bazu se bira iz skupine koju čine trietilamin, 1,5-diazabiciklo[4.3.O0]non-5-en; 1,4-diazabiciklo[2.2.2]oktan; i 1,8-diazabiciklo[5.4.O0]undec-7-en; te smjese 2 ili višo njih.
The compound of Claim 6, where R3 is hydrogen, fluoro, chloro, or methyl; R4 is hydrogen, fluoro, chloro, or bromo; R5 is hydrogen or fluoro; and R6 is hydrogen, fluoro, chloro, or bromo. 
Spoj u skladu s patentnim zahtjevom 6, naznačen time, da je R3 vodik, fluoro, kloro ili metil; R4 je vodik, fluoro, kloro ili bromo; R5 je vodik ili fluoro; a R6 je vodik, fluoro, kloro ili bromo.
0.5-4% by weight on a dry weight basis of magnesium stearate. 
od 0,1 do 2 masena postotka na bazi suhe mase magnezijevog stearata;
The pharmaceutical composition of the above (3.), wherein the pharmaceutical composition is suitable for intravenous administration. 
Farmaceutska kompozicija patentnog zahtjeva 3, gdje je farmaceutska kompozicija pogodna za intravensku administraciju.
The compound as recited in any one or more of claims 1 to 5, wherein said compound is a mixture of at least two diastereomers, a first diastereomer and a second diastereomer; wherein said first and second diastereomers are otherwise identical, except that said first and second diastereomers have different stereochemical configurations at a chiral phosphorus atom; wherein said chiral phosphorus atom is a phosphorus atom that is bound to a sulfur atom. 
Tvar kako je nabrojena u jednom ili više od patentnih zahtjeva 1 do 5, pri čemu je navedena tvar smjesa najmanje dva dijastereoizomera, prvi dijastereoizomer i drugi dijastereoizomer; pri čemu su navedeni prvi i navedeni drugi dijastereoizomeri inače identični, osim što navedeni prvi 1 drugi dijastereoizomeri imaju različite stereokemijske konfiguracije na kiralnom atomu fosfora; pri čemu je navedeni kiralni atom fosfora atom koji je vezan na atom sumpora.
18 The method according to any of the above clauses wherein the weight gain is induced by administration of an atypical antipsychotic. 
Spoj za uporabu sukladno patentnom zahtjevu 1, naznačeno time, da je dobivanje na težini inducirano primjenom netipičnog antipsihotika.
Preferably, the solvent is ethyl acetate. 
Poželjno, otapalo je etil acetat.
In another embodiment the present disclosure provides a method of inhibiting growth, proliferation, or metastasis of cancer cells in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of a compound of formula (I) or a therapeutically acceptable salt thereof. 
Spoj iz patentnog zahtjeva 1 ili njegova terapijski prihvatljiva sol za primjenu u inhibiranju rasta, proliferacije, ili metastaze kancerogenih stanica kod subjekta kod kojeg postoji potreba za tim.
Phosphorous pentachloride (32.8 g, 157.5 mmol, 2.5 eq) was added in portions over 30 minutes to a stirred solution of the reduced tetrabenazine product from Example 1A (20 g, 62.7 mmol) in dichloromethane (200 ml) at 0 °C. 
Fosfor pentaklorid (32.8 g, 157.5 mmol, 2.5 ekvivalenta) se dodaje u obrocima tijekom 30 minuta u miješanu otopinu reduciranog tetrabenazin produkta iz Primjera 1A (20 g, 62.7 mmol) u diklorometanu (200 ml) na 0%C.
Analytical HPLC was conducted on a Supelcosil LCABZ+PLUS column (3.3 cm x 4.6 mm ID), eluting with 0.1% HCO2H and 0.01 M ammonium acetate in water (solvent A), and 0.05% HCO2H 5% water in acetonitrile (solvent B), using the following elution gradient: 0-0.7 minutes 0%B, 0.7-4.2 minutes 0%-100%B, 4.2-5.3 minutes 100%B, 5.3-5.5 minutes 0%B at a flow rate of 3 ml/minute. 
Analitički HPLC proveden je stupcu Supelcosil LCABZ+PLUS (3,3 cm x 4,6 mm, unutarnji promjer), uz eluiranje s 0,1 % HCOzH i 0,01 M amonijevim acetatom u vodi (otapalo A), te 0,05 % HCO;H 5 % vodom u acetonitrilu (otapalo B), uz sljedeći elucijski gradijent: 0-0,7 minuta 0 % B, 0,7-4,2 minute 0 %-100 % B, 4,2-5,3 minute 100 % B, 5,3-5,5 minuta 0 % B, pri brzini protoka od 3 ml/min.
granulating the active ingredient trituration of step (1) by adding the granulation liquid, preferably water; 
(2) granuliranje triturata aktivnog sastojka iz koraka (1) dodavanjem granulacijske tekućine, povoljno je vode;
The composition of claim 31, further comprising a therapeutic agent selected from an immunomodulatory agent, a hormonal agent, a chemotherapeutic agent, an anti-angiogenic agent, an apoptotic agent, a second antibody that binds to and inhibits an inhibitory KIR receptor, an anti -infective agent, a targeting agent or an adjunct compound. 
Oblik prema zahtjevu 31, koji dalje sadrži terapijsko sredstvo izabrano između imunomodulatornog sredstva, hormona, kemoterapijskog sredstva, anti-angiogeničnog sredstva, apoptotičnog sredstva, drugog protutijela koje veže 1 inhibira taj inhibitorni KIR receptor, anti-infektivnog sredstva, ciljnog sredstva ili dodatnog spoja.
In an alternative embodiment the invention provides a bispecific single chain antibody comprising a first domain binding domain capable of binding to CD3 epsilon (CD3e) of human and non-chimpanzee primate and a second domain binding domain capable of binding to the extracellular domain of the mutated human FAPa chimera having an amino acid sequence as depicted in SEQ ID NO: 448 but not to the extracellular domain of the rodent FAPa. 
(b) vežuća domena, koja se može vezati na izvanstaničnu domenu kimere mutiranog ljudskog FAPa s aminokiselinskim slijedom kao što je opisan u SEQ ID NO: 448, gdje su aminokiselinski ostaci na položajima 144, 185, 186, 229, 267, 273, 274, 278, 284, 301, 328, 329, 331, 335 1 362 mutirani u odgovarajuće aminokiselinske ostatke FAPa divljeg tipa glodavca, no ne i na izvanstaničnu domenu FAPa divljeg tipa;
For this purpose the invention provides a method of constructing a building in accordance with claim 1. 
Za ovu svrhu, predmetni izum nudi postupak gradnje građevine u skladu sa patentnim zahtjevom 1.
The term "3,11b- cis -" as used herein means that the hydrogen atoms at the 3- and 11 b-positions of the dihydrotetrabenazine structure are in the cis relative orientation. 
Izraz "3,11b-cis" kako se ovdje koristi podrazumijeva da su vodikovi atomi strukture dihidrotetrabenazina na položajima 3-1 11b-u cis relativnoj orijentaciji kako je to prikazano u Formuli (1) ispod.
In one of the embodiments of the invention, domain (a) and domain (b) are linked by at least one domain (c) comprising the sequence of a cleavage site recognized by proteases present in the cell environment, especially in the tumor cell environment. 
Fuzijski protein prema bilo kojem od zahtjeva 1 do 3, naznačen time da fuzijski protein između domene (a) i domene (b) sadrži domenu (c) koja obuhvaća mjesto cijepanja proteaze, odabranu od sekvence koju prepoznaje metaloproteaza MMP, sekvence koju prepoznaje urokinaza uPA, te njihove kombinacije.
A bed arrangement including adaptive properties, the bed arrangement comprising: 
Krevet (1) koji ima prilagodljiva svojstva, koji obuhvaća:
(c2) adding the remaining irbesartan hydrochloride and optionally further excipient (s) to the granulate to obtain a compression mixture; 
* (62) dodavanjem preostalog irbesartan hidroklorida i po izboru daljnjih pomoćnih tvari u granulat da bi se dobila smjesa za komprimiranje; te (ili) komprimiranje smjese za komprimiranje u željeni oblik.
An example of a compound of the invention is: 
Datum podnošenja europske prijave patenta:
The compound of Claim 1, wherein the compound is selected from; and or a pharmaceutically acceptable salt of any of the foregoing. 
[image] Spoj 104; [image] Spoj 120; i [image] Spoj 123 ili farmaceutski prihvatljive soli bilo kojeg od naprijed navedenih spojeva.
GSK3B (glycogen synthase kinase 3B) is a proline directed serine, threonine kinase that plays an important role in the control of metabolism, differentiation and survival. 
GSK3P (glikogen-sintaza-kinaza 3f) je prolinski ovisna serinska/treoninska kinaza, koja ima važnu ulogu u kontroli metabolizma, diferentijacije 1 preživljavanja.
reducing lead ions in the lead ion-enriched electroprocessing solvent on a cathode to form adherent high-purity lead and a regenerated electroprocessing solvent without significant anodic destruction of the chelator, which means less than 10% chelator loss per 12 hr continuous operation; removing the adherent high-purity lead from one portion of the cathode while lead ions are reduced on another portion of the cathode; 
reduciranje iona olova u ionom olova obogaćenog elektroprocesorskom otapalu na katodi da bi se tvorio prijanjajuže olovo visoke čistoće i regenerirano elektroprocesorsko otapalo bez značajnog anodnog uništenja kelatora, što znači manje od 10% gubitka kelatora na 12 sati neprekidnog rada; uklanjanje prijanjajućeg olova visoke čistoće iz jednog dijela katode pri čemu su ioni olova reducirani na drugom dijelu katode;
The ship propulsion system as defined in claim 1, wherein: the electrolysis chamber and a pipeline system are formed from the electrolysis chamber to the gasification tank so that hydrogen gas and oxygen gas can be conveyed, unseparated, as oxyhydrogen. 
Brodski propulzijski sustav sukladno zahtjevu 1 ili 2, naznačen time, da su komora za elektrolizu (20) i cjevovodi sustav formirani od komora za elektrolizu (20) plinskog spremnika (30) tako da plin vodik i plin kisika mogu biti preneseni, neodvojeni, kao elektrolitički plin.
Inactivation due to hydrolysis is minimal due to the lower lability of the ketomethylenic or thioketomethylenic group, allowing a longer half-life. 
Inaktivacija zbog hidrolize je najmanje uslijed niže labilnosti ketometilenske ili tioketometilenske skupine, što omogućava duži poluživot.
a tilting frame (24) which is connected to the lifting frame (45) in order to determine a tilting axle (13) about which the spud (3) can be tilted, 
okvir za naginjanje (24), spojen s okvirom za podizanje (45) radi određivanja osi naginjanja (13) oko koje se kolac (3) može nagnuti, -
Analysis of the results: 
Broj objave europskog patenta:
The pharmaceutical composition according to claim 15, wherein said adjuvant is selected from the group of colony-stimulating factors, such as Granulocyte Macrophage Colony Stimulating Factor (GM- CSF). 
Farmaceutski sastav sukladno tvrdnji 15, pri čemu se spomenuto pomoćno sredstvo odabire iz skupine kolonija stimulativnih faktora, kao što je granulocit makrofag kolonija stimulativni faktor (3GM-CSF).
(m-2) adding water and an alcohol selected from methanol, ethanol, isopropanol and n-propanol (particularly isopropanol) and allowing crystallisation of the compound of the Formula X to occur, collecting the compound of the Formula X and washing the compound of the Formula X with a mixture of water and the alcohol selected from methanol, ethanol, isopropanol and n-propanol, followed by a solvent selected from ethyl acetate, butyl acetate and acetonitrile at a temperature in the range of from 25 to 55° C., conveniently 25 to 55° C.; 
C; ili (m-2) dodavanja vode i alkohola izabranog od metanola, etanola, izopropanola i n-propanola i dozvoljavanja kristalizacije spoja formule X, i sakupljanja spoja formulom X i pranja spoja sa formulom X sa mješavinom vode i alkohola izabranog od metanola, etanola, izopropanola i n-propanola, a nakon toga sa otapalom izabranim između 20
Figure 3 shows in sectional view details of a second embodiment of a beverage dispensing assembly according to the invention. 
Slika 3 prikazuje u presjeku pojedinosti druge izvedbe sklopa za točenje pića prema izumu.
A volume of 600 ml of the formulation ET-NF-H was prepared as follows: mg of ET-743 were added to a compounding glass vessel and dissolved by magnetical stirring in a solution of 480 ml wfi+1.44 ml of 1N phosphoric acid for approximately 1 h (dissolution was checked visually). 
Zapremina od 600 ml oblika ET-NF-H pripremljena je na sljedeći način: 62.76 mg ET-743 dodano je u staklenu posudu za miješanje i otopljeno magnetnim miješanjem u otopini od 480 ml wfi + 1.44 ml 1N fosforne kiseline za približno 1 sat (otapanje je provjeravano vizualno).
A compound having the general formula I wherein, R1 is H, CONR4R5; 
Spoj koji ima opću formulu I [image] gdje,
when in the compound of Formula (IV) Z is cyano, COOR5 or CH2OR5, converting said compound to a compound of Formula (IV) wherein Z is CHO; 
kada u spoju formule (IV) Z jest cijano, COOR5 ili CH2OR5, pretvaranje navedenog spoja u spoj formule (IV), u čemu Z jest CHO;
one coated tablet comprising 81 mg acetylsalicylic acid, two coated tablets each comprising 20 mg simvastatin and one coated tablet comprising 5 mg ramipril; 
jedna obložena tableta koja sadrži 81 mg acetilsalicilatne kiseline, dvije obložene tablete od kojih svaka sadrži 20 mg simvastatina i jedna obložena tableta koja sadrži 5 mg ramiprila;
The compound-linker molecule according to claim 8 having a structure represented by formula (VI-o) 
Tvar molekula poveznik u skladu s patentnim zahtjevom 8 koja ima strukturu predstavljenu formulom (VI-o):
A kit comprising i) the device according to any one of examples 1-28; ii) a material suitable for injection into the human body. 
Oprema koja sadržava 1) uređaj koji je u skladu s bilo kojim od patentnih zahtjeva 1 - 29; 11) materijal koji je prikladan za injektiranje u ljudsko tijelo.
The application provides a kit for isothermally amplifying a nucleic acid target molecule comprising an upstream primer, a downstream primer, a strand invasion system and an oligonucleotide, wherein the upstream and downstream primers are not substrates for the strand invasion system during the amplification process and do not amplify the target molecule independently of the strand invasion system, wherein the oligonucleotide is a substrate for the strand invasion system. 
(c) rekombinaza; pri čemu uzvodna 1 nizvodna početnica ne pojačavaju ciljnu molekulu neovisno od stanja oligonukleotida, kada se oligonukleotid dovodi u kontakt s rekombinazom, on napada ciljanu molekulu dvolančane nukleinske kiseline, pri tome daje komplementarnu regiju jednolančanu ciljanu molekulu i susjedne regije čime se omogućava početnicama pristup za vezivanje komplementarne jednolančane DNK na ciljanu molekulu.
A long term evolved, LTE, network, comprising: a user equipment, UE, a serving gateway, SGW, a source evolved NodeB, eNB, and a target eNB, wherein the target eNB is configured to acquire a GPRS Tunneling Protocol User, GTP_U, sequence number of a next user data packet to be sent by a source eNB and a GTP_U sequence number of a first user data packet sent by the SGW, determine an end of sending user data packets by the source eNB to the target eNB according to the GTP_U sequence number of the next user data packet to be sent by the source eNB and the GTP_U sequence number of the first user data packet sent by the SGW, and send user data packets delivered by the SGW to the UE. 
jedinicu koja određuje specijalni paket podataka (1220), konfiguriranu da određuje da li je specijalni paket podataka sa završnom oznakom primljen od strane izvorišnog eNB, pri čemu poseban paket podataka ne sadrži pakete korisničkih podataka i poseban paket podataka je generiran od strane SGW i šalje se prema izvorišnom eNB nakon što SGW provede komutaciju puta i završna oznaka je postavljena u zaglavlje posebnog paketa podataka da se označi kraj slanja paketa korisničkih podataka; i jedinicu koja šalje paket korisničkih podataka (1230), konfiguriranu da šalje pakete korisničkih podataka isporučene od SGW primljene od jedinicu koja prima pakete korisničkih podataka (1210) do korisničke opreme, UE, kada jedinica koja određuje specijalni paket podataka (1220) utvrdi da je primljen poseban paket podataka.
conjugating a cytotoxic agent to the cell-binding agents having linkers bound thereto in the purified first mixture by reacting the cell-binding agents having linkers bound thereto with a cytotoxic agent in a solution having a pH of about 4 to about 9 to prepare a second mixture comprising (i) cell-binding agent chemically coupled through the linker to the cytotoxic agent, (ii) free cytotoxic agent, and (iii) reaction by-products, and 
(c) konjugacije maitanzinoida sa antitijelima koja imaju za sebe vezane linkere u pročišćenoj prvoj smjesi putem reakcije antitijela koja imaju za sebe vezane linkere sa maitanzinoidom u otopini koja ima pH od 4 do 9 da bi se pripremila druga smjesa koja sadrži (i) antitijelo kemijski spojeno preko linkera za maitanzinoid, (1i) slobodan maitanzinoid i (iii) sporedne proizvode reakcije, 1
provided that, when Ar2 is A1), combinations of the substituents R6, R7 and R8 exclude a combination of a hydrogen atom and a halogen atom. The compound according to [4] or a pharmacologically acceptable salt thereof, wherein R1 is a hydrogen atom, a hydroxy group, a C1 to C6 alkyl group, a C1 to C6 alkoxy group, a halo-C1 to C6 alkyl group, a hydroxy C1 to C6 alkyl group, a carboxy C1 to C6 alkyl group, a carbamoyl C1 to C6 alkyl group, a mono C1 to C6 alkylcarbamoyl C1 to C6 alkyl group, a di-C1 to C6 alkylcarbamoyl C1 to C6 alkyl group, an aminosulfonyl C1 to C6 alkyl group, an aromatic heterocyclic C1 to C3 alkyl group optionally having substituent (s), or a phenyl C1 to C3 alkyl group optionally having substituent(s); 
Spoj u skladu sa patentnim zahtjevom 4 ili njegova farmakološki prihvatljiva sol, ili njegov solvat ili hidrat, gdje izraz "po izboru ima supstituent(e)" ima značenje definirano u patentnom zahtjevu 1, i gdje R' je atom vodika, hidroksi grupa, Cy do C4 alkil grupa, Cy do C4 alkoksi grupa, halo-C, do Cxy alkil grupa, hidroksi C, do Cg alkil grupa, karboksi C, do Cg alkil grupa, karbamoil €, do C4 alkil grupa, mono C; do Cg alkilkarbamoil C; do Cg alkil grupa, di-Ci do CÂ« alkilkarbamoil C; do C4 alkil grupa, aminosulfonil C, do Cg alkil grupa, aromatična heterociklična C, do C3 alkil grupa koja po izboru ima supstituent(e), ili fenil Ci do C3 alkil grupa koja po izboru ima supstituent(e);
The method of preparation of alkenyl triphenylphosphonium derivatives of tamoxifen of the general formula IA is based on preparation of ylide generated from alkyl bis(triphenylphosphonium) of the general formula VIII where n=7 to 11 
Način pripreme alkil trifenil fosfonijskih derivata tamoksifena opće formule I prema zahtjevu 1 odlikuje se time, da ilid generirani iz tert-butildimefilsili-oksi-alkil-trifenil fosfonija opće formule II, a. oo
A composition comprising an orodispersible dose of 25 µg or 50 µg desmopressin measured as the free base of desmopressin, for use in reducing nocturnal voids in a male patient in need thereof, wherein the dose is for administration to the patient prior to bedtime and reduces the patient's nocturnal voids compared to before administration, and wherein the mean reduction of nocturnal voids at week 52 of administration is increased compared to the mean reduction in nocturnal voids at day 28 of administration. 
PATENTNI ZAHTJEVI M» Pripravak koji sadrži orodisperzibilnu dozu od 25 ug ili 50 ug desmopresina mjerenu kao slobodnu bazu desmopresina, za upotrebu u smanjenju nokturije kod muškog pacijenta kojem je to potrebno, pri čemu je doza za davanje pacijentu prije spavanja i smanjuje noćna buđenja kod pacijenta u usporedbi s prije primjene, te pri čemu se srednje smanjenje noćnih buđenja u 52. tjednu primjene povećava u usporedbi sa srednjim smanjenjem noćnih buđenja 28. dana primjene.
wherein, where the third polymeric material is a non-ionic polymer, the inner coating preparation comprises at least one additive selected from the group consisting of a buffer agent and a base. 
Formulacija lijeka s odloženim otpuštanjem sukladno patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačeno time, da unutarnji sloj sadrži najmanje jedno pufersko sredstvo i najmanje jednu bazu.
Arginine for use according to claim 3, characterized in that it is administered in form of tablet, capsule, granule, granulate, powder, tablet, gel capsule, solution, suspension, emulsion, drops, syrup, powder for solutions, granules for solutions, granulate for suspensions, or powder for suspensions. 
Arginin, namijenjen upotrebi u skladu s patentnim zahtjevom 3, naznačen time što se primjenjuje u obliku tablete, kapsule, granule, granulata, praha, tablete, kapsule s gelom, otopine, suspenzije, emulzije, kapi, sirupa, praha za otopine, granula za otopine, granulata za suspenzije ili praha za suspenzije.
An monoclonal antibody or antigen binding fragment thereof, which binds to at least three different CC chemokines, wherein at least one CC chemokine is CCL3/MIP-1a, CCL4/MIP-1B, or CCL5/RANTES, wherein the antibody or antigen binding fragment thereof: 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, koji se veže na najmanje tri različita CC kemokina, naznačeno time, da je najmanje jedan CC kemokin CCL3/MIP-1a, CCL4/MIP-B it CCLS/RANTES, pri čemu antitijelo ili fragment koji veže antigen: